Patents by Inventor Boopathy Ramakrishnan

Boopathy Ramakrishnan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody molecules to CD138 and uses thereof
    Patent number: 11945868
    Abstract: Antibody molecules that specifically bind to CD138 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: April 2, 2024
    Assignee: VISTERRA, INC.
    Inventors: Bharat Chaganty, Boopathy Ramakrishnan, Hedy Adari-Hall, Karthik Viswanathan, James R. Myette, Zachary Shriver
  • ANTIBODY MOLECULES TO APRIL AND USES THEREOF
    Publication number: 20240092921
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Application
    Filed: April 24, 2023
    Publication date: March 21, 2024
    Inventors: David William Oldach, James R. Myette, Zachary Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock, Jill Yarbrough, Asher Schachter, Mohit Mathur
  • Antibody Molecules to C5AR1 and Uses Thereof
    Publication number: 20240076398
    Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
    Type: Application
    Filed: August 18, 2023
    Publication date: March 7, 2024
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • Humanized complement 5A receptor 1 antibodies and methods of use thereof
    Patent number: 11912781
    Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: February 27, 2024
    Assignee: Visterra, Inc.
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver, Lauren Olinski
  • Antibody molecule-drug conjugates and uses thereof
    Patent number: 11890319
    Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: February 6, 2024
    Assignee: VISTERRA, INC.
    Inventors: Zachary Shriver, Obadiah Joseph Plante, Kai Li, Karthik Viswanathan, James C. Delaney, Boopathy Ramakrishnan, Andrew M. Wollacott
  • Engineered polypeptides and uses thereof
    Patent number: 11858980
    Abstract: Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: January 2, 2024
    Assignee: VISTERRA, INC.
    Inventors: Karthik Viswanathan, Boopathy Ramakrishnan, Brian Booth, Kristin Narayan, Andrew M. Wollacott
  • ENGINEERED ANTIBODY MOLECULES TO CD138 AND USES THEREOF
    Publication number: 20230348614
    Abstract: Antibody molecules that specifically bind to CD138 in a tumor microenvironment (e.g., at acidic pH) are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.
    Type: Application
    Filed: November 23, 2022
    Publication date: November 2, 2023
    Inventors: James R. Myette, Boopathy Ramakrishnan, Bharat Chaganty, Brahm Yachnin
  • Antibody molecules to C5aR1 and uses thereof
    Patent number: 11773179
    Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: October 3, 2023
    Assignee: VISTERRA, INC.
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFLUENZA
    Publication number: 20230257449
    Abstract: This disclosure relates to binding agents, e.g., antibody molecules, that bind hemagglutinin protein of influenza viruses, and methods of their use.
    Type: Application
    Filed: December 11, 2020
    Publication date: August 17, 2023
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew M. Wollacott, Gregory Babcock, Zachary Shriver
  • HUMANIZED COMPLEMENT 5A RECEPTOR 1 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220356263
    Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.
    Type: Application
    Filed: January 13, 2022
    Publication date: November 10, 2022
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • ANTIBODY MOLECULE-DRUG CONJUGATES AND USES THEREOF
    Publication number: 20220267418
    Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.
    Type: Application
    Filed: October 8, 2021
    Publication date: August 25, 2022
    Inventors: Obadiah Joseph Plante, James C. Delaney, Karthik Viswanathan, Boopathy Ramakrishnan, Zachary Holmes Shriver, Andrew M. Wollacott
  • ANTIBODY MOLECULES TO A PROLIFERATION-INDUCING LIGAND (APRIL)
    Publication number: 20220235124
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Application
    Filed: August 31, 2021
    Publication date: July 28, 2022
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock
  • INTERLEUKIN-2 AGENTS AND USES THEREOF
    Publication number: 20220226442
    Abstract: IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
    Type: Application
    Filed: January 20, 2022
    Publication date: July 21, 2022
    Inventors: Scott Moore Carlson, Gregory Babcock, Zachary Shriver, Boopathy Ramakrishnan, Susan Sloan
  • METHODS OF USING INTERLEUKIN-2 AGENTS
    Publication number: 20220177535
    Abstract: IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
    Type: Application
    Filed: December 3, 2021
    Publication date: June 9, 2022
    Inventors: Scott Moore Carlson, Gregory Babcock, Zachary Shriver, Boopathy Ramakrishnan, Thiago de Jesus Borges, Leonardo Vidal Riella
  • Antibody Molecules to C5AR1 and Uses Thereof
    Publication number: 20220089764
    Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
    Type: Application
    Filed: January 13, 2021
    Publication date: March 24, 2022
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • METHODS FOR IDENTIFYING EPITOPES AND PARATOPES
    Publication number: 20220059184
    Abstract: Disclosed are methods of identifying an epitope on a target polypeptide and methods of identifying a paratope on an antibody.
    Type: Application
    Filed: December 23, 2019
    Publication date: February 24, 2022
    Inventors: Andrew M. Wollacott, Luke Robinson, Boopathy Ramakrishnan, Hamid Tissire, Karthik Viswanathan, Zachary Shriver, Gregory Babcock
  • Antibody molecule-drug conjugates and uses thereof
    Patent number: 11168131
    Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: November 9, 2021
    Assignee: VISTERRA, INC.
    Inventors: Obadiah Joseph Plante, James C. Delaney, Karthik Viswanathan, Boopathy Ramakrishnan, Zachary Holmes Shriver, Andrew M. Wollacott
  • ANTIBODY MOLECULES TO APRIL AND USES THEREOF
    Publication number: 20210340266
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Application
    Filed: June 24, 2021
    Publication date: November 4, 2021
    Inventors: James R. Myette, Zachary Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock, Jill Yarbrough, Asher Schachter, Mohit Mathur
  • ANTIBODY MOLECULE-DRUG CONJUGATES AND USES THEREOF
    Publication number: 20210316004
    Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.
    Type: Application
    Filed: April 2, 2021
    Publication date: October 14, 2021
    Inventors: Karthik Viswanathan, Kenneth Douglas Johnson, Obadiah Joseph Plante, James C. Delaney, Tyree J. Koch, Hamid Tissire, Andrew M. Wollacott, Boopathy Ramakrishnan
  • Methods of treating IgA nephropathy by administering an anti-APRIL (a proliferation-inducing ligand) antibody molecule
    Patent number: 11136385
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: October 5, 2021
    Assignee: VISTERRA, INC.
    Inventors: James R. Myette, Zachary Holmes Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock